Invexans S.A. | Income Statement
Fiscal year is January-December. All values CLP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
403,785.90
384,114.40
241,019.70
40,574.10
1,946.70
19,903.30
Cost of Goods Sold (COGS) incl. D&A
192,727.30
115,291.40
92,347.20
6,086.10
648.90
642
Gross Income
211,058.60
268,823.00
148,672.50
34,488.00
1,297.80
19,261.20
SG&A Expense
1,693,919.00
2,482,760.30
2,192,755.10
1,740,628.50
1,567,122.20
3,840,049.90
EBIT
1,491,778.30
2,213,937.30
2,044,082.70
1,706,140.50
2,241,341.60
4,797,975.80
Unusual Expense
410,226.60
14,099,224.80
3,186,306.40
389,511.30
174,557.30
228,566.80
Non Operating Income/Expense
8,775,778.50
1,006,231.40
421,784.40
402,359.70
1,602,812.30
39,164.50
Interest Expense
1,246,534.10
1,715,673.00
339,261.40
332,707.50
294,606.00
247,186
Pretax Income
5,667,865.70
18,962,581.30
5,117,738.60
1,218,575.20
1,023,982.90
5,129,269.20
Income Tax
979,490.40
489,132.30
48,465.90
143,361.80
955,847.20
147,669.50
Equity in Affiliates
50,542,102.80
23,671,264.60
36,782,354.10
10,466,762.90
23,634,019.10
3,313,575.90
Consolidated Net Income
45,853,727.50
42,144,713.50
41,851,626.80
9,104,826.00
23,565,883.40
8,590,514.60
Net Income
45,853,727.50
42,144,713.50
41,851,626.80
9,104,826.00
23,565,883.40
8,590,514.60
Net Income After Extraordinaries
45,853,727.50
42,144,713.50
41,851,626.80
9,104,826.00
23,565,883.40
8,590,514.60
Net Income Available to Common
45,853,727.50
42,144,713.50
41,851,626.80
9,104,826.00
23,565,883.40
8,590,514.60
EPS (Basic)
6.19
2.57
1.83
0.41
1.04
0.39
Basic Shares Outstanding
7,422,000.00
16,247,826.80
22,422,000.00
22,422,000.00
22,422,000.00
22,264,779.20
EPS (Diluted)
6.18
2.59
1.87
0.41
1.05
0.39
Diluted Shares Outstanding
7,422,000.00
16,247,826.80
22,422,000.00
22,422,000.00
22,422,000.00
22,264,779.20
EBITDA
1,413,002.90
2,125,471.10
1,964,834.40
1,702,759.30
2,240,692.70
4,797,333.70
Other Operating Expense
8,918.00
-
-
-
675,517.30
977,187.10
Non-Operating Interest Income
40,626.30
72,485.20
30,127.50
28,401.90
83,709.60
105,294.80
About Invexans
View Profile
